Eyenovia Inc. touted data from its phase II study evaluating the safety and efficacy of its high-precision ophthalmic microtherapeutics compared to conventional eyedropper treatment. The trial comes on the heels of a previous phase II study published in Therapeutic Delivery in October.
New York-based Eyenovia’s trial demonstrated that its microdosing achieved superior pharmacologic effects and bioavailability compared to dropper therapy, while reducing ocular side effects to 8% versus 66% for conventional topical treatment.
Get the full story at our sister site, Drug Delivery Business News.
The post Eyenovia touts phase II study data appeared first on MassDevice.